48 studies found for:    "Zollinger-Ellison Syndrome"
Show Display Options
Rank Status Study
21 Recruiting Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Pancreatic Cancer;   Somatostatinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: capecitabine;   Drug: temozolomide;   Biological: bevacizumab
22 Not yet recruiting Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: dovitinib lactate;   Other: pharmacological study;   Other: laboratory biomarker analysis
23 Recruiting Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Islet Cell Carcinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: temozolomide;   Drug: capecitabine;   Other: laboratory biomarker analysis
24 Active, not recruiting Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Paraganglioma;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Neuroendocrine Carcinoma of the Skin;   Regional Gastrointestinal Carcinoid Tumor;   Somatostatinoma;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin;   Thyroid Gland Medullary Carcinoma
Interventions: Biological: cixutumumab;   Drug: octreotide acetate;   Drug: everolimus;   Other: pharmacological study;   Other: laboratory biomarker analysis
25 Recruiting Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Biological: ziv-aflibercept;   Radiation: computed tomography perfusion imaging;   Other: laboratory biomarker analysis
26 Active, not recruiting Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Alpha Cell Carcinoma;   Pancreatic Beta Islet Cell Adenoma;   Pancreatic Beta Islet Cell Carcinoma;   Pancreatic Delta Cell Adenoma;   Pancreatic Delta Cell Carcinoma;   Pancreatic G-cell Adenoma;   Pancreatic G-cell Carcinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Pancreatic Cancer;   Somatostatinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: everolimus;   Drug: octreotide acetate;   Biological: bevacizumab
27 Active, not recruiting Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Neuroendocrine Tumor;   Pancreatic Polypeptide Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma;   WDHA Syndrome
Intervention: Drug: sorafenib tosylate
28 Completed The Acute Effect of Coffee Consumption on Stomach, Self-reported Gastrointestinal Symptoms and Stress.
Conditions: Stress;   Signs and Symptoms, Digestive;   Blood Pressure;   Increased Secretion of Gastrin
Interventions: Other: Cold espresso;   Other: Hot instant coffee;   Other: Cold instant coffee;   Other: Hot filter coffee
29 Active, not recruiting Capecitabine and Temozolomide for Neuroendocrine Cancers
Condition: Neuroendocrine Tumors
Intervention: Drug: Capecitabine and temozolomide
30 Completed
Has Results
A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.
Condition: Healthy
Interventions: Drug: Clopidogrel;   Drug: Clopidogrel and Lansoprazole;   Drug: Clopidogrel and Dexlansoprazole;   Drug: Clopidogrel and Omeprazole;   Drug: Clopidogrel and Esomeprazole
31 Completed Cinacalcet to Treat Familial Primary Hyperparathyroidism
Conditions: Hypercalcemia;   Familial Primary Hyperparathyroidism
Interventions: Procedure: Parathyroid hormone testing;   Procedure: Serum calcium testing
32 Completed Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Conditions: Brain and Central Nervous System Tumors;   Breast Cancer;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Lung Cancer;   Lymphoma;   Melanoma (Skin);   Neoplastic Syndrome
Intervention: Radiation: yttrium Y 90-edotreotide
33 Active, not recruiting Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Lung Cancer;   Neoplastic Syndrome;   Neuroendocrine Tumor
Interventions: Biological: bevacizumab;   Drug: 5-fluorouracil;   Drug: leucovorin;   Drug: oxaliplatin
34 Unknown  Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Interventions: Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
35 Completed PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor
Intervention: Drug: bortezomib
36 Completed Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Condition: Cancer
Interventions: Biological: trastuzumab;   Drug: tipifarnib
37 Completed Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor
Interventions: Drug: capecitabine;   Drug: cisplatin;   Drug: streptozocin;   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: protein analysis;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis
38 Unknown  Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Conditions: Brain and Central Nervous System Tumors;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neuroblastoma;   Pheochromocytoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Radiation: yttrium Y 90-edotreotide
39 Completed EPO906 in Carcinoid and Other Neuroendocrine Tumors
Conditions: Carcinoid;   Neuroendocrine Tumors
Intervention: Drug: EPO906 epothilone B
40 Unknown  AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Interventions: Drug: motesanib diphosphate;   Drug: octreotide acetate;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis;   Procedure: computed tomography

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-48) Show next page of results    Last Page
Indicates status has not been verified in more than two years